Company

Gongwin Biopharm Holdings Co. Ltd

Headquarters: Taipei, Taiwan

TWSE: 6617 +1.39%

Market Cap

TW$18.45 Billion

TWD as of July 1, 2024

US$566.5 Million

Market Cap History

Gongwin Biopharm Holdings Co. Ltd market capitalization over time

Evolution of Gongwin Biopharm Holdings Co. Ltd market cap in the past 5 years

Market capitalizations are calculated from the opening stock price at the beginning of each month.

Market Cap History of Gongwin Biopharm Holdings Co. Ltd

Detailed Description

Gongwin Biopharm Holdings Co., Ltd., a clinical-stage biopharmaceutical company, develops anticancer drugs. It is developing PTS302, which has completed Phase III clinical trials for the treatment of lung cancer; PTS100, which is in Phase II clinical trials for the treatment of liver cancer; PTS-02 for the treatment of adenoid cystic carcinoma; and PTS500 for the treatment of malignant pleural effusion. The company was founded in 2014 and is based in Taipei, Taiwan.

Top 1-year algo backtest: +265.99%

$10,000 in October 2023 would now be $36,599 by following this algorithm daily at market close.

Use AI to boost your investing & swing trading, now!

Try Disfold DeepFinance FREE

Stocks & Indices

Gongwin Biopharm Holdings Co. Ltd has the following listings and related stock indices.


Stock: TWSE: 6617 wb_incandescent

Details

Headquarters:

No. 80, Jianguo North Road

3rd Floor Section 1 Zhongshan District

Taipei, 10491

Taiwan

Phone: 886 2 2503 5282